Circulation. 2002;106:2827-2835
Published online before print November 11, 2002, doi: 10.1161/01.CIR.0000039325.03698.36
Published online before print November 11, 2002, doi: 10.1161/01.CIR.0000039325.03698.36
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:2827.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice
From the Division of Surgical Science, Department of Surgery (L.G.B., T.W., W.Q., Y.L., L.R., M.T.G., B.M., T.K., D.C.L., Y.K., D.M.S., A.M.S.); Department of Physiology & Cellular Biophysics (D.M.S.), College of Physicians & Surgeons; and Division of Periodontics, School of Dental & Oral Surgery (E.L.), Columbia University, New York, NY.
Correspondence to Dr Ann Marie Schmidt, Department of Surgery, College of Physicians & Surgeons, Columbia University, 630 West 168th St, P&S 17-401, New York, NY 10032. E-mail ams11{at}columbia.edu
Background— Previous studies suggested that blockade of RAGE in diabetic apolipoprotein (apo) E–null mice suppressed early acceleration of atherosclerosis. A critical test of the potential applicability of RAGE blockade to clinical settings was its ability to impact established vascular disease. In this study, we tested the hypothesis that RAGE contributed to lesion progression in established atherosclerosis in diabetic apoE-null mice.
Methods and Results— Male apoE-null mice, age 6 weeks, were rendered diabetic with streptozotocin or treated with citrate buffer. At age 14 weeks, certain mice were killed or treated with once-daily murine soluble RAGE or albumin; all mice were killed at age 20 weeks. Compared with diabetic mice at age 14 weeks, albumin-treated animals displayed increased atherosclerotic lesion area and complexity. In diabetic mice treated with sRAGE from age 14 to 20 weeks, lesion area and complexity were significantly reduced and not statistically different from those observed in diabetic mice at age 14 weeks. In parallel, decreased parameters of inflammation and mononuclear phagocyte and smooth muscle cell activation were observed.
Conclusions— RAGE contributes not only to accelerated lesion formation in diabetic apoE-null mice but also to lesion progression. Blockade of RAGE may be a novel strategy to stabilize atherosclerosis and vascular inflammation in established diabetes.
Key Words: diabetes mellitus • inflammation • muscle, smooth • atherosclerosis
Related Article:
Circulation 2002 106: 2760-2763.
This article has been cited by other articles:
 |
|
 |
|
  H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson, and M. Lambert Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases Rheumatology, July 9, 2009; (2009) kep199v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Lindsey, J. A. de Lemos, F. Cipollone, C. R. Ayers, A. Rohatgi, D. A. Morrow, A. Khera, and D. K. McGuire Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis: Observations from the Dallas Heart Study Diabetes Care, July 1, 2009; 32(7): 1218 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chew, D. Y.C. Yuen, P. Koh, N. Stefanovic, M. A. Febbraio, I. Kola, M. E. Cooper, and J. B. de Haan Site-Specific Antiatherogenic Effect of the Antioxidant Ebselen in the Diabetic Apolipoprotein E-Deficient Mouse Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sun, T. Ishida, T. Yasuda, Y. Kojima, T. Honjo, Y. Yamamoto, H. Yamamoto, S. Ishibashi, K.-i. Hirata, and Y. Hayashi RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice Cardiovasc Res, May 1, 2009; 82(2): 371 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B Lindsey, F. Cipollone, S. M Abdullah, and D. K Mcguire Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications Diabetes and Vascular Disease Research, January 1, 2009; 6(1): 7 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Shanmugam, M. A. Reddy, and R. Natarajan Distinct Roles of Heterogeneous Nuclear Ribonuclear Protein K and microRNA-16 in Cyclooxygenase-2 RNA Stability Induced by S100b, a Ligand of the Receptor for Advanced Glycation End Products J. Biol. Chem., December 26, 2008; 283(52): 36221 - 36233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Katakami, M. Matsuhisa, H. Kaneto, T.-A. Matsuoka, K. Sakamoto, T. Yasuda, and Y. Yamasaki Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 190 - 197. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Yamoah, A. Brebene, R. Baliram, K. Inagaki, G. Dolios, A. Arabi, R. Majeed, H. Amano, R. Wang, R. Yanagisawa, et al. High-Mobility Group Box Proteins Modulate Tumor Necrosis Factor-{alpha} Expression in Osteoclastogenesis via a Novel Deoxyribonucleic Acid Sequence Mol. Endocrinol., May 1, 2008; 22(5): 1141 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Spinetti, N. Kraenkel, C. Emanueli, and P. Madeddu Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies Cardiovasc Res, May 1, 2008; 78(2): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Goh and M. E. Cooper The Role of Advanced Glycation End Products in Progression and Complications of Diabetes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1143 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Heinonen, P. Leppanen, I. Kholova, H. Lumivuori, S.-K. Hakkinen, F. Bosch, M. Laakso, and S. Yla-Herttuala Increased Atherosclerotic Lesion Calcification in a Novel Mouse Model Combining Insulin Resistance, Hyperglycemia, and Hypercholesterolemia Circ. Res., November 9, 2007; 101(10): 1058 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-V. Cantero, M. Portero-Otin, V. Ayala, N. Auge, M. Sanson, M. Elbaz, J.-C. Thiers, R. Pamplona, R. Salvayre, and A. Negre-Salvayre Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-{beta}: implications for diabetic atherosclerosis FASEB J, October 1, 2007; 21(12): 3096 - 3106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Marsche, B. Weigle, W. Sattler, and E. Malle Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein FASEB J, October 1, 2007; 21(12): 3075 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ohtaki, W. Kamitani, Y. Watanabe, Y. Hayashi, H. Yanai, K. Ikuta, and K. Tomonaga Downregulation of an Astrocyte-Derived Inflammatory Protein, S100B, Reduces Vascular Inflammatory Responses in Brains Persistently Infected with Borna Disease Virus J. Virol., June 1, 2007; 81(11): 5940 - 5948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Kanter, F. Johansson, R. C. LeBoeuf, and K. E. Bornfeldt Do Glucose and Lipids Exert Independent Effects on Atherosclerotic Lesion Initiation or Progression to Advanced Plaques? Circ. Res., March 30, 2007; 100(6): 769 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Koyama, T. Shoji, S. Fukumoto, K. Shinohara, T. Shoji, M. Emoto, K. Mori, H. Tahara, E. Ishimura, R. Kakiya, et al. Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cuccurullo, A. Iezzi, M. L. Fazia, D. De Cesare, A. Di Francesco, R. Muraro, R. Bei, S. Ucchino, F. Spigonardo, F. Chiarelli, et al. Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2716 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Basta, A. M. Sironi, G. Lazzerini, S. Del Turco, E. Buzzigoli, A. Casolaro, A. Natali, E. Ferrannini, and A. Gastaldelli Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4628 - 4634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shanmugam, R. M. Ransohoff, and R. Natarajan Interferon-{gamma}-inducible Protein (IP)-10 mRNA Stabilized by RNA-binding Proteins in Monocytes Treated with S100b J. Biol. Chem., October 20, 2006; 281(42): 31212 - 31221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Raman, P. L. Sappington, R. Yang, R. M. Levy, J. M. Prince, S. Liu, S. K. Watkins, A. M. Schmidt, T. R. Billiar, and M. P. Fink The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock Am J Physiol Gastrointest Liver Physiol, October 1, 2006; 291(4): G556 - G565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fujita, H. Okuda, O. Tsukamoto, Y. Asano, Y. L. A. Hirata, J. Kim, T. Miyatsuka, S. Takashima, T. Minamino, H. Tomoike, et al. Blockade of Angiotensin II Receptors Reduces the Expression of Receptors for Advanced Glycation End Products in Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): e138 - e139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhong, S.-H. Li, S.-M. Liu, P. E. Szmitko, X.-Q. He, P. W.M. Fedak, and S. Verma C-Reactive Protein Upregulates Receptor for Advanced Glycation End Products Expression in Human Endothelial Cells Hypertension, September 1, 2006; 48(3): 504 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury Circulation, August 8, 2006; 114(6): 597 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Goldberg and H. M. Dansky Diabetic Vascular Disease: An Experimental Objective Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1693 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Reddy, S.-L. Li, S. Sahar, Y.-S. Kim, Z.-G. Xu, L. Lanting, and R. Natarajan Key Role of Src Kinase in S100B-induced Activation of the Receptor for Advanced Glycation End Products in Vascular Smooth Muscle Cells J. Biol. Chem., May 12, 2006; 281(19): 13685 - 13693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sato, N. Shimogaito, X. Wu, S. Kikuchi, S.-i. Yamagishi, and M. Takeuchi Toxic Advanced Glycation End Products (TAGE) Theory in Alzheimer's Disease American Journal of Alzheimer's Disease and Other Dementias, May 1, 2006; 21(3): 197 - 208. [Abstract] [PDF]
|
|
|
|
|
|
P. M. Humpert, S. Kopf, Z. Djuric, T. Wendt, M. Morcos, P. P. Nawroth, and A. Bierhaus Plasma sRAGE Is Independently Associated With Urinary Albumin Excretion in Type 2 Diabetes Diabetes Care, May 1, 2006; 29(5): 1111 - 1113. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wang, Z. Zhou, M. Zhang, L. Fan, F. Forudi, X. Zhou, W. Qu, A. M. Lincoff, A. M. Schmidt, E. J. Topol, et al. Peroxisome Proliferator-Activated Receptor {gamma} Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Werstuck, M. I. Khan, G. Femia, A. J. Kim, V. Tedesco, B. Trigatti, and Y. Shi Glucosamine-Induced Endoplasmic Reticulum Dysfunction Is Associated With Accelerated Atherosclerosis in a Hyperglycemic Mouse Model Diabetes, January 1, 2006; 55(1): 93 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Koyama, T. Shoji, H. Yokoyama, K. Motoyama, K. Mori, S. Fukumoto, M. Emoto, T. Shoji, H. Tamei, H. Matsuki, et al. Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2587 - 2593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. DeVries-Seimon, Y. Li, P. M. Yao, E. Stone, Y. Wang, R. J. Davis, R. Flavell, and I. Tabas Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor J. Cell Biol., October 10, 2005; 171(1): 61 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lawrie, E. Spiekerkoetter, E. C. Martinez, N. Ambartsumian, W. J. Sheward, M. R. MacLean, A. J. Harmar, A.-M. Schmidt, E. Lukanidin, and M. Rabinovitch Interdependent Serotonin Transporter and Receptor Pathways Regulate S100A4/Mts1, a Gene Associated With Pulmonary Vascular Disease Circ. Res., August 5, 2005; 97(3): 227 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology, July 1, 2005; 15(7): 16R - 28R. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby, D. M. Nathan, K. Abraham, J. D. Brunzell, J. E. Fradkin, S. M. Haffner, W. Hsueh, M. Rewers, B. T. Roberts, P. J. Savage, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus Circulation, June 28, 2005; 111(25): 3489 - 3493. [Full Text] [PDF]
|
|
|
|
|
|
B. I. Hudson, E. Harja, B. Moser, and A. M. Schmidt Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease: The Next C-Reactive Protein? Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 879 - 882. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Zieman, V. Melenovsky, and D. A. Kass Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 932 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Falcone, E. Emanuele, A. D'Angelo, M. P. Buzzi, C. Belvito, M. Cuccia, and D. Geroldi Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1032 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Kilhovd, A. Juutilainen, S. Lehto, T. Ronnemaa, P. A. Torjesen, K. I. Birkeland, T. J. Berg, K. F. Hanssen, and M. Laakso High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men: A Population-Based 18-Year Follow-Up Study Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 815 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis Matrix Metalloproteinases and Diabetic Vascular Complications Angiology, March 1, 2005; 56(2): 173 - 189. [Abstract] [PDF]
|
|
|
|
|
|
N. Kalinina, A. Agrotis, Y. Antropova, G. DiVitto, P. Kanellakis, G. Kostolias, O. Ilyinskaya, E. Tararak, and A. Bobik Increased Expression of the DNA-Binding Cytokine HMGB1 in Human Atherosclerotic Lesions: Role of Activated Macrophages and Cytokines Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2320 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Basta, A. M. Schmidt, and R. De Caterina Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes Cardiovasc Res, September 1, 2004; 63(4): 582 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Naka, L. G. Bucciarelli, T. Wendt, L. K. Lee, L. L. Rong, R. Ramasamy, S. F. Yan, and A. M. Schmidt RAGE Axis: Animal Models and Novel Insights Into the Vascular Complications of Diabetes Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Forbes, L. T. L. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, M. C. Thomas, W. C. Burns, E. K. Deemer, S. R. Thorpe, et al. Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis Diabetes, July 1, 2004; 53(7): 1813 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Burke, F. D. Kolodgie, A. Zieske, D. R. Fowler, D. K. Weber, P. J. Varghese, A. Farb, and R. Virmani Morphologic Findings of Coronary Atherosclerotic Plaques in Diabetics: A Postmortem Study Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1266 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-F. Yan, R. Ramasamy, L. G Bucciarelli, T. Wendt, L. K Lee, B. I Hudson, D. M Stenr, E. Lalla, S. Du Yan, L. L. Rong, et al. RAGE and its ligands: a lasting memory in diabetic complications? Diabetes and Vascular Disease Research, May 1, 2004; 1(1): 10 - 20. [Abstract] [PDF]
|
|
|
|
|
|
F. Cipollone, B. Rocca, and C. Patrono Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 246 - 255. [Abstract] [Full Text]
|
|
|
|
|
|
S. F. Yan, R. Ramasamy, Y. Naka, and A. M. Schmidt Glycation, Inflammation, and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and Beyond Circ. Res., December 12, 2003; 93(12): 1159 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Chavakis, A. Bierhaus, N. Al-Fakhri, D. Schneider, S. Witte, T. Linn, M. Nagashima, J. Morser, B. Arnold, K. T. Preissner, et al. The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins: A Novel Pathway for Inflammatory Cell Recruitment J. Exp. Med., November 17, 2003; 198(10): 1507 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shanmugam, Y. S. Kim, L. Lanting, and R. Natarajan Regulation of Cyclooxygenase-2 Expression in Monocytes by Ligation of the Receptor for Advanced Glycation End Products J. Biol. Chem., September 12, 2003; 278(37): 34834 - 34844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cipollone, A. Iezzi, M. Fazia, M. Zucchelli, B. Pini, C. Cuccurullo, D. De Cesare, G. De Blasis, R. Muraro, R. Bei, et al. The Receptor RAGE as a Progression Factor Amplifying Arachidonate-Dependent Inflammatory and Proteolytic Response in Human Atherosclerotic Plaques: Role of Glycemic Control Circulation, September 2, 2003; 108(9): 1070 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, A. Zalewski, Y. Liu, T. Mazurek, S. Cowan, J. L. Martin, S. M. Hofmann, H. Vlassara, and Y. Shi Diabetes-Induced Oxidative Stress and Low-Grade Inflammation in Porcine Coronary Arteries Circulation, July 29, 2003; 108(4): 472 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Kass Getting Better Without AGE: New Insights Into the Diabetic Heart Circ. Res., April 18, 2003; 92(7): 704 - 706. [Full Text] [PDF]
|
|
|
|
|
|
P. Libby and J. Plutzky Diabetic Macrovascular Disease: The Glucose Paradox? Circulation, November 26, 2002; 106(22): 2760 - 2763. [Full Text] [PDF]
|
|